Expression of Mcl-1 and Ki-67 in Papillary Thyroid Carcinomas.

Autor:	Maia FF; Endocrinology Division, Department of Internal Medicine, University of Campinas, São Paulo, Brazil., Vassallo J; Department of Pathology, Medical Science School, University of Campinas, São Paulo, Brazil., Pinto GA; Laboratory of Specialized Pathology, CAISM, University of Campinas, São Paulo, Brazil., Pavin EJ; Endocrinology Division, Department of Internal Medicine, University of Campinas, São Paulo, Brazil., Matos PS; Department of Pathology, Medical Science School, University of Campinas, São Paulo, Brazil., Zantut-Wittmann DE; Endocrinology Division, Department of Internal Medicine, University of Campinas, São Paulo, Brazil.
Jazyk:	angličtina
Zdroj:	Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association [Exp Clin Endocrinol Diabetes] 2016 Apr; Vol. 124 (4), pp. 209-14. Date of Electronic Publication: 2016 Apr 28.
DOI:	10.1055/s-0035-1569363
Abstrakt:	Unlabelled: Studying molecules that are differentially expressed in cancers as well as benign and normal tissues is crucial for identifying novel biomarkers for cancer immunotherapy. This study aimed to investigate the clinical utility of the immunochemical expression of the proliferative cell marker Ki-67 and the apoptotic blocker Mcl-1 in papillary thyroid carcinoma (PTC). Methods: We built a tissue microarray with 282 thyroid specimens. There were 59 PTCs including 35 classic (CPTC), 3 tall cell (TCPTC) and 21 follicular variants (FVPTC); 79 benign thyroid diseases (22 follicular adenomas; 57 adenomatoid hyperplasia); 33 Hashimoto's thyroiditis (HT) specimens; and 111 normal thyroid tissues. Clinical history and ultrasound data were retrospectively obtained by chart review. Results: Mcl-1 overexpression was evident in 66.7% of the PTC tissues compared to 32% of the benign thyroid diseases. Mcl-1 strong staining distinguished benign from malignant thyroid lesions (sensitivity=61.3%; specificity=72.8%; negative predictive value, NPV=68%; positive predictive value, PPV=66.7% and 67.5% accuracy). Positive nuclear Ki-67 staining was observed in 34% of PTCs vs. 19% of thyroid adenomas (P=0.031). Strong Mcl-1 and Ki-67 co-expression was identified in 57.5% of PTCs with a higher PPV (75.8%). Mcl-1 and Ki-67 expression was not associated with any clinicopathological feature of malignancy. No deaths occurred during the follow-up. Conclusions: Mcl-1 immunochemical overexpression allowed differentiating low-risk PTC from the benign thyroid lesions. We suggest that Mcl-1 expression may help differentiate follicular patterned thyroid lesions. The influence of the Mcl-1 expression on several features of tumor aggressiveness has to be studied in large series of high-risk thyroid carcinomas. (© Georg Thieme Verlag KG Stuttgart · New York.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu